United Osteoporosis Center
Industry / private company
Location:
Gainesville, GA,
United States (USA) (US)
ISNI: -
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial (2021)
Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, Nogues X, et al.
Journal article
Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass (2017)
Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, Goemaere S, et al.
Journal article
Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology (2015)
Zysset P, Pahr D, Engelke K, Genant HK, Mcclung MR, Kendler DL, Recknor C, et al.
Journal article
Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab (2014)
Keaveny TM, Mcclung MR, Genant HK, Zanchetta JR, Kendler D, Brown JP, Goemaere S, et al.
Journal article